<DOC>
	<DOCNO>NCT02256852</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , compliance mechanism action study drug ( QBKPN SSI ) subject two second primary pre-invasive invasive adenocarcinoma follow surgical section Stage 1 NSCLC .</brief_summary>
	<brief_title>Exploratory Study QBKPN SSI Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Please refer summary .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Male female age consent Histologically confirm original diagnosis lung cancer Life expectancy great 12 month ECOG performance status 0 , 1 , 2 screen Female subject agree practice two effective method contraception time sign informed consent form one month last dose study drug Male subject agree practice effective barrier contraception entire study drug period one month last dose study drug Extrathoracic lung cancer progression Any active malignancy Any uncontrolled major organ dysfunction Any past current radiation systemic therapy treatment lung cancer Known HIV infection immunosuppressive disorder Concurrently participate another study investigational immunotherapy receive investigational immunotherapy within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>